498 related articles for article (PubMed ID: 34817311)
1. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.
Shubrook JH; Neumiller JJ; Wright E
Postgrad Med; 2022 May; 134(4):376-387. PubMed ID: 34817311
[TBL] [Abstract][Full Text] [Related]
2. Non-steroidal mineralocorticoid antagonists and hyperkalemia monitoring in chronic kidney disease patients associated with type II diabetes: a narrative review.
Morales J; Palmer BF
Postgrad Med; 2024 Mar; 136(2):111-119. PubMed ID: 38344772
[TBL] [Abstract][Full Text] [Related]
3. High unmet treatment needs in patients with chronic kidney disease and type 2 diabetes: real-world evidence from a US claims database.
Fried L; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Kovesdy C
Nephrol Dial Transplant; 2023 Feb; 38(3):630-643. PubMed ID: 35389468
[TBL] [Abstract][Full Text] [Related]
4. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape.
Mende CW
Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711
[TBL] [Abstract][Full Text] [Related]
5. Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes.
Skolnik NS; Style AJ
Diabetes Ther; 2021 Jun; 12(6):1613-1630. PubMed ID: 33914300
[TBL] [Abstract][Full Text] [Related]
6. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.
Edmonston D; Lydon E; Mulder H; Chiswell K; Lampron Z; Marsolo K; Goss A; Ayoub I; Shah RC; Chang AR; Ford DE; Jones WS; Fonesca V; Machineni S; Fort D; Butler J; Hunt KJ; Pitlosh M; Rao A; Ahmad FS; Gordon HS; Hung AM; Hwang W; Bosworth HB; Pagidipati NJ
JAMA Netw Open; 2024 Jun; 7(6):e2418808. PubMed ID: 38922613
[TBL] [Abstract][Full Text] [Related]
7. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
8. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study.
Chu L; Fuller M; Jervis K; Ciaccia A; Abitbol A
Clin Ther; 2021 Sep; 43(9):1558-1573. PubMed ID: 34426012
[TBL] [Abstract][Full Text] [Related]
10. How Would You Manage This Patient With Type 2 Diabetes and Chronic Kidney Disease? Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana GW; Romeo GR; Rosas SE; Burns RB
Ann Intern Med; 2024 Jun; 177(6):800-811. PubMed ID: 38857499
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications and guidelines for CKD in type 2 diabetes.
Zhang RM; Persson F; McGill JB; Rossing P
Nephrol Dial Transplant; 2023 Feb; 38(3):542-550. PubMed ID: 36264310
[TBL] [Abstract][Full Text] [Related]
12. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).
de Boer IH; Khunti K; Sadusky T; Tuttle KR; Neumiller JJ; Rhee CM; Rosas SE; Rossing P; Bakris G
Kidney Int; 2022 Nov; 102(5):974-989. PubMed ID: 36202661
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of an investigator-initiated, multicenter, prospective open-label, randomized trial to evaluate the effect of ipragliflozin on endothelial dysfunction in type 2 diabetes and chronic kidney disease: the PROCEED trial.
Tanaka A; Shimabukuro M; Okada Y; Sugimoto K; Kurozumi A; Torimoto K; Hirai H; Node K;
Cardiovasc Diabetol; 2020 Jun; 19(1):85. PubMed ID: 32534578
[TBL] [Abstract][Full Text] [Related]
14. Management of type 2 diabetes in chronic kidney disease.
Triozzi JL; Parker Gregg L; Virani SS; Navaneethan SD
BMJ Open Diabetes Res Care; 2021 Jul; 9(1):. PubMed ID: 34312158
[TBL] [Abstract][Full Text] [Related]
15. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
[TBL] [Abstract][Full Text] [Related]
16. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update.
Navaneethan SD; Zoungas S; Caramori ML; Chan JCN; Heerspink HJL; Hurst C; Liew A; Michos ED; Olowu WA; Sadusky T; Tandon N; Tuttle KR; Wanner C; Wilkens KG; Craig JC; Tunnicliffe DJ; Tonelli M; Cheung M; Earley A; Rossing P; de Boer IH; Khunti K
Ann Intern Med; 2023 Mar; 176(3):381-387. PubMed ID: 36623286
[TBL] [Abstract][Full Text] [Related]
17. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients.
Spasovski G; Rroji M; Hristov G; Bushljetikj O; Spahia N; Rambabova Bushletikj I
Metab Syndr Relat Disord; 2024 Apr; 22(3):170-178. PubMed ID: 38386800
[TBL] [Abstract][Full Text] [Related]
18. Estimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.
Rossing P; Groehl F; Mernagh P; Folkerts K; Garreta-Rufas A; Harris J; Meredith K; Carter M; Åkerborg Ö; Wanner C; Hobbs FDR
J Med Econ; 2023; 26(1):935-943. PubMed ID: 37439218
[TBL] [Abstract][Full Text] [Related]
19. Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria.
McGill JB; Haller H; Roy-Chaudhury P; Cherrington A; Wada T; Wanner C; Ji L; Rossing P
BMJ Open Diabetes Res Care; 2022 Jul; 10(4):. PubMed ID: 35790319
[TBL] [Abstract][Full Text] [Related]
20. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
